Why the study?
The review discusses the clinical implications of olmesartan medoxomil as an optimal choice as monotherapy and combination therapy in managing patients with hypertension.
Does olmesartan-based therapy reduce blood pressure in adults with hypertension?
Does olmesartan-based therapy reduce blood pressure in adults with hypertension?
This review highlights olmesartan as an effective and well-tolerated option for blood pressure control in adults with hypertension.
Olmesartan supports 24-hour BP control in hypertension; leaves open head-to-head outcomes versus newer agents.
For >3 decades now, angiotensin receptor blockers (ARB) have been used in the management of hypertension (HTN) and HTN-related cardiovascular (CV) diseases. Olmesartan medoxomil (OLM) is an angiotensin II type 1 (AT1) receptor antagonist (or blocker) that binds tightly to the AT1 receptor with long-lasting efficacy over the 24-hour period and safety demonstrated in several trials. It is well tolerated and effective in reducing blood pressure (BP) in mono and combination therapy with thiazide diuretics or calcium channel blockers across a wide range of patient subgroups. The effectiveness and safety of OLM-based combination therapies have good and tolerable profiles with high adherence in the fixed single-pill formulation. Consistent antihypertensive efficacy and good tolerability when used as monotherapy or as a combined therapy make OLM a valuable treatment option for adults with HTN. In this review, we discuss the important clinical implications of OLM as an optimal choice as monotherapy and combination therapy in managing patients with HTN.
No takes yet. Share an insight, caveat, or question.
Tiwaskar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: